Royalty Pharma (RPRX) has made strategic changes to streamline its corporate structure through a
$1.1 billion deal. Despite a mixed outlook by industry analysts, the company's stock saw an increase, following a management buyout and announcement of a
$3 billion buyback plan. This move is projected to save the company
$1.6 billion. Additionally, the company raised its dividend by 5%. It's notable that Royalty Pharma is largely dominated by
institutional shareholders who own 70% of the company. The pharma company posted robust earnings with 15% revenue growth and has solid institutional backing. Yet, there have been bearish signals with insiders disposing of stock. The company strategically invested in the FDA-approved cancer drug, RYTELO, securing a $125M deal. Market analysts have noted a possible massive opportunity ahead for the firm, despite recent stock performance hitting a 52-week low at $24.7. Recently, Syndax Pharmaceuticals and Royalty Pharma entered a
$350 million royalty funding agreement for Niktimvo™. Lastly,
Jim Cramer has called the performance of the company 'disappointing' but recommends holding the stock, stating, ’I want you to stick with it.
Royalty Pharma Stocks News Analytics from Tue, 16 Jun 2020 07:00:00 GMT to Sat, 11 Jan 2025 19:11:19 GMT -
Rating 5
- Innovation 7
- Information 9
- Rumor -5
